REFERENCES
- Clavel F. HIV Drug resistance. N Eng' J Med. 2004;350(10): 1023–1032.
- Lawrence J, Mayers D, Huppler Hullsiek K, et al. Structured treatment interruption in patients with multidrug-resistant HIV. N Engl J Med. 2003;349(9):837–846.
- Gunthard H, von Wyl V, Yerly S, et al. Virologic failure and emergence of treatment specific HIV-1 drug resistance patterns on first line HAART in previously untreated pa-tients from the Swiss HIV Cohort Study. Antiviral Ther. 2006;11:S82.
- Hogg R, Bangsberg D, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med. 2006;3: 1570–1577.
- Recsky MA, Brumme ZL, Chan KJ, et al. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral ther-apy. J Infect Dis. 2004;190:285–292.
- Lucas GM. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is wo-ven. J Antimicrobial Chemother 2005;55(4):413–416.
- Lucas GM, Gallant JE, Moore RD. Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing. AIDS. 2004:18: 1539–1548.
- Zaccarelli M, Tozzi V, Lorenzini P, et al. Multiple drug class-wide resistance associated with poorer survival after treat-ment failure in a cohort of HIV-infected patients. AIDS. 2005;19(10):1081–1089.
- Ormassen V, Sandvik L, Asjo B, et al. An algorithm-based genotypic resistance score is associated with clinical out-come in HIV-1-infected adults on antiretroviral therapy. HIV Med. 2004;5(6):400–406.
- MacArthur RD, Novak RM, Peng G, et al. Long-term clinical and immunologic outcomes are similar in HIV-infected persons randomized to NNRTI versus PI ver-sus NNRTI+Pl-based antiretroviral regimens as initial therapy: results of the CPCRA 058 FIRST Study. Lancet. 2006;368:2125–2135.
- MacArthur RD, Chen L, Mayers DL, et al., for the CPCRA 058 FIRST Trial Study Team. The rationale and design of the CCPRA 058 Trial. Control Clin Trials. 2001,22: 176–190.
- Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med. 2005;13:51–57.
- Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiol-ogy. 2000;11:550–560.
- Hernan MA, Brumback B, Robins JM. Marginal struc-tural models to estimate the causal effect of zidovu-dine on the survival of HIV-positive men. Epidemiology. 2000;11:561–570.
- Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Enql J Med. 2003;349:2304–2315.
- Zaccarelli M, Forbicib F, Lorenzinia P. Continuous evidence of fast HIV disease progression related to class-wide re-sistance to antiretroviral drugs: a 6 year follow-up analy-sis of a large observational database. AIDS. 2007;21(13): 1824–1826.
- Deeks SG, Barbour JD, Martin J, et al. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis. 2000;181:946–953.
- Deeks S G, Wrin T, Liegler T, et al. Virologic and im-munologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. New Engl J Med. 2001344: 472–480.
- Deeks S G, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 1999;13:F35—F43.
- Bangsberg DR, Acosta E, Gupta R, et al. Viral replication capacity under varying adherence-adjusted Cmin drug lev-els explains differing NNRTI and PI adherence/resistance relationships. In: Program and abstracts of the 13th Con-ference on Retroviruses and Opportunistic Infections; Feb-ruary 5–8, 2006; Denver, Colorado, USA. Abstract 631.
- Bangsberg D R, Charlebois ED, Grant RM, et al. High lev-els of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS. 2003;17:1925–1932.
- Novak RM, Chen L, MacArthur RD, et al., for the CPCRA 058 Study Team. Prevalence of antiretroviral drug resis-tance mutations in chronically HIV-infected, treatment na-lye participants in the CPCRA FIRST Study: implications for routine resistance screening prior to initiating antiretro-viral therapy. Clin Infect Dis. 2005;40(3):468–474.
- Desai SS, Kyriakides TC, Holodniy M, Al-Salman J, Griffith B, Kozal MJ. Evolution of genotypic resistance algorithms and their impact on the interpretation of clinical trials: an OPTIMA Trial substudy. HIV Clin Trials. 2007;8(5):293–302.